Remission of migraine attacks in a patient with depression who is taking pregabalin

Clinical Neuropharmacology

Volumn 31, Issue 4, 2008, Pages 238-240

  Masdrakis, Vasilios G ^a,b   Oulis, Panagiotis ^a   Karakatsanis, Nikolaos A ^a   Potagas, Constantin ^a   Kouzoupis, Anastasios V ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antiepileptic drugs; Migraine; Pregabalin

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; CODEINE; ESCITALOPRAM; GABAPENTIN; MEFENAMIC ACID; PARACETAMOL; PREGABALIN; TOPIRAMATE; VALPROATE SEMISODIUM; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; DRUG DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR DEPRESSION; MIGRAINE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; REMISSION; SYMPTOM; DEPRESSION; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME;

ANALGESICS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; TREATMENT OUTCOME;

EID: 53449093881     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31814a62e1     Document Type: Article

References (16)

1. Hung CI, Liu CY, Juang YY, et al. The impact of migraine on patients with major depressive disorder. Headache 2006;46:469-477.
2. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-2538.
3. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6: 57-75.
4. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol 2006;26:188-198.
5. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;3:CD003226.
6. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007;47(suppl 1):S52-S57.
7. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003;12: 663-672.
8. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-2037.
9. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006;16:S128-S133.
10. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2 delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73:137-150.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
12. Headache Classification Subcommittee of the International Headache Society. International classification of headache disorders, 2nd ed. Cephalalgia 2004;24(suppl 1):8-152.
13. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128.
14. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007;4:75-83.
15. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000;151:145-148.
16. Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension type headaches. Cochrane Database Syst Rev 2005;3:CD002919.